[go: up one dir, main page]

CU23810A3 - Sustancias inmunogénicas que comprenden un adyuvante a base de ácido poliinosínico-ácido policitidílico - Google Patents

Sustancias inmunogénicas que comprenden un adyuvante a base de ácido poliinosínico-ácido policitidílico

Info

Publication number
CU23810A3
CU23810A3 CU20080135A CU20080135A CU23810A3 CU 23810 A3 CU23810 A3 CU 23810A3 CU 20080135 A CU20080135 A CU 20080135A CU 20080135 A CU20080135 A CU 20080135A CU 23810 A3 CU23810 A3 CU 23810A3
Authority
CU
Cuba
Prior art keywords
acid
polytidylic
understanding
polyinosinic
immunogenic substances
Prior art date
Application number
CU20080135A
Other languages
English (en)
Inventor
Lie Tao Victor Li
Haixiang Lin
Original Assignee
Yisheng Biopharma Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yisheng Biopharma Singapore Pte Ltd filed Critical Yisheng Biopharma Singapore Pte Ltd
Publication of CU23810A3 publication Critical patent/CU23810A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención provee una composición de polinucleótido adyuvante (PICKCa) para provocar una respuesta inmunológica. El polinucleótido adyuvante consiste de ácido polirriboinosínico-polirribocitidílico (PIC), el antibiótico kanamicina e iones calcio. La presente invención provee también una composición inmunogénica que comprende la composición de polinucleótido adyuvante junto con un antígeno viral.
CU20080135A 2006-01-13 2008-07-14 Sustancias inmunogénicas que comprenden un adyuvante a base de ácido poliinosínico-ácido policitidílico CU23810A3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/331,575 US20070166800A1 (en) 2006-01-13 2006-01-13 Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant

Publications (1)

Publication Number Publication Date
CU23810A3 true CU23810A3 (es) 2012-04-15

Family

ID=38256597

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20080135A CU23810A3 (es) 2006-01-13 2008-07-14 Sustancias inmunogénicas que comprenden un adyuvante a base de ácido poliinosínico-ácido policitidílico

Country Status (16)

Country Link
US (4) US20070166800A1 (es)
EP (1) EP1971402A4 (es)
JP (1) JP2009523721A (es)
KR (1) KR20080091106A (es)
CN (1) CN101166559B (es)
AU (1) AU2006335367B2 (es)
BR (1) BRPI0621181A8 (es)
CA (1) CA2632415A1 (es)
CU (1) CU23810A3 (es)
IL (1) IL192746A0 (es)
MY (1) MY150706A (es)
NZ (1) NZ570379A (es)
RU (1) RU2462264C2 (es)
TW (1) TWI503125B (es)
WO (1) WO2007081287A1 (es)
ZA (1) ZA200806339B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101203401B1 (ko) * 2005-06-08 2012-11-22 이쉥 바이오파마(싱가포르)피티이 리미티드 폴리이노신산-폴리시티딜산-기초 보조제
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
CA2715293A1 (en) * 2008-02-15 2009-08-20 Hemispherx Biopharma, Inc. Selective agonist of toll-like receptor 3
RU2440140C1 (ru) * 2010-12-09 2012-01-20 Иосиф Григорьевич Атабеков Иммуногенная композиция, содержащая чужеродные антигены на поверхности сферических носителей, полученных при термической денатурации спиральных вирусов
RU2441667C1 (ru) * 2010-12-09 2012-02-10 Иосиф Григорьевич Атабеков Новый тип частиц-носителей (платформ) для получения активных комплексов
US9303068B2 (en) 2012-11-30 2016-04-05 The Regents Of The University Of California D-amino acid derivative-modified peptidoglycan and methods of use thereof
WO2014186291A1 (en) * 2013-05-14 2014-11-20 Zoetis Llc Novel vaccine compositions comprising immunostimulatory oligonucleotides
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
US20170340727A1 (en) 2014-12-23 2017-11-30 Yisheng Biopharma (Singapore) Pte Ltd A Rabies Composition Comprising Pika Adjuvant
US9913800B2 (en) * 2015-04-28 2018-03-13 The Procter & Gamble Company Compositions and methods for improving skin health
CN105396130A (zh) * 2015-11-10 2016-03-16 林海祥 皮氨钙佐剂及含有皮氨钙佐剂的疫苗
WO2017085228A1 (en) * 2015-11-17 2017-05-26 Bioncotech Therapeutics, S.L Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
CN106075431A (zh) * 2016-03-23 2016-11-09 林海祥 皮氨钙联合佐剂及含有皮氨钙联合佐剂的疫苗
CN107198777A (zh) * 2016-04-01 2017-09-26 依生生物制药(新加坡)私人有限公司 用于治疗癌症的含有聚核苷酸的药物组合物
CN106075432A (zh) * 2016-04-27 2016-11-09 林海祥 皮卡钙联合佐剂及含有皮卡钙联合佐剂的疫苗
US11020419B2 (en) * 2016-09-30 2021-06-01 Biosyngen Pte, Ltd Use of polyinosinic-polycytidylic acid compositions in treatment of malignant effusion
CA3063805C (en) * 2017-05-17 2024-01-09 Bioncotech Therapeutics Sl Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
CN109125264B (zh) 2017-06-19 2020-10-30 林海祥 一种抗感染抗肿瘤的粘膜免疫制剂
MX2020001226A (es) * 2017-08-10 2020-07-20 Yisheng Biopharma Singapore Pte Ltd Una composicion para tratar y/o prevenir la infeccion por el virus de la hepatitis b y su metodo.
WO2020001587A1 (zh) 2018-06-29 2020-01-02 信福(北京)医药科技有限公司 用于增强免疫响应的复合物
CN109078180B (zh) * 2018-06-29 2019-05-31 信福(北京)医药科技有限公司 用于增强免疫响应的复合物
CN109663126A (zh) * 2019-03-01 2019-04-23 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
KR20230013133A (ko) * 2020-05-29 2023-01-26 베이징 이셍 바이오테크놀로지 컴퍼니 엘티디. 폴리뉴클레오타이드를 포함하는 약물조성물 및 그 covid-19 예방 또는 치료에 사용되는 용도
WO2021243248A2 (en) * 2020-05-29 2021-12-02 Children's Medical Center Corporation Adjuvants for severe acute respiratory syndrome-related coronavirus (sars-cov) vaccines
KR20250105443A (ko) * 2022-11-09 2025-07-08 제노 테라퓨틱스 피티이 엘티디 면역 세포 요법을 개선하기 위한 폴리이노신산-폴리시티딜산, 엡스타인-바 바이러스(ebv) 유사 입자 및 ebv 특이적 car-t 세포를 포함하는 조성물

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692899A (en) * 1969-12-17 1972-09-19 Us Health Education & Welfare Inhibition of transplanted tumor growth by polyinosinic-polycytidylic acid in mice
US3666646A (en) * 1970-05-15 1972-05-30 Merck & Co Inc Reduction of molecular weight in polynucleotides using ultrasonic radiation
US4124702A (en) * 1971-07-06 1978-11-07 Merck & Co., Inc. Polynucleotides active as inducers of interferon production in living animal cells
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US4186194A (en) * 1973-10-23 1980-01-29 Agence Nationale De Valorisation De La Recherche (Anvar) Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
US4024241A (en) * 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US3952097A (en) * 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
FR2321896A1 (fr) * 1975-08-29 1977-03-25 Anvar Agents adjuvants immunologiques actifs en solution aqueuse
US4153684A (en) * 1976-03-10 1979-05-08 Agence Nationale De Valorisation De La Recherche (Anvar) Immunizing and anti-infectious adjuvant agents constituted by N-acetyl-muramyl-L-alanyl-D-glutamic acid derivatives
US4082735A (en) * 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
US4082736A (en) * 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
GB1563561A (en) * 1976-06-23 1980-03-26 Daiichi Seiyaku Co Muramyldipeptide derivatives and process for the preparation thereof
FR2368282A1 (fr) * 1976-10-22 1978-05-19 Anvar Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine
US4140761A (en) * 1977-04-11 1979-02-20 The United States Of America As Represented By The Department Of Health, Education & Welfare Modification of hepatitis B virus infection in chronic carriers of hepatitis B surface antigen
JPS55111499A (en) * 1979-02-21 1980-08-28 Takeda Chem Ind Ltd Glucosamine derivative and its preparation
CA1185237A (en) * 1979-02-28 1985-04-09 Yuichi Yamamura 6-deoxyglucosamine-peptide derivatives, their production and use
NZ194880A (en) 1979-09-17 1983-07-15 Merck & Co Inc Interferon-inducing composition containing modified polyriboinosinic-polyribocytidylic acid
US4349538A (en) * 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
FR2476488A2 (fr) 1980-02-25 1981-08-28 Government Us America Nouveau complexe hydrophile, resistant aux nucleases, d'acide polyriboinosinique-polyribocytidylique, son procede de preparation et son application comme inducteur d'interferon
JPS572220A (en) 1980-06-09 1982-01-07 Toray Ind Inc Production of interferon
US4389395A (en) * 1981-01-09 1983-06-21 Lerner A Martin Low molecular weight complex of polyriboinosinic-polyribocytidylic acid and method of inducing interferon
US4400375A (en) * 1981-11-23 1983-08-23 Eli Lilly And Company Tobramycin-double stranded RNA complex suitable for inducing interferon
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4857315A (en) * 1986-09-29 1989-08-15 Mount Sinai Hospital Corporation Compositions containing golgi alpha-mannosidase II inhibitors
JPH01186818A (ja) 1988-01-18 1989-07-26 Yamasa Shoyu Co Ltd ポリリボイノシン酸・ポリリボシチジル酸・ポリ−ｌ−リジン複合体製剤
US5230883A (en) * 1989-05-04 1993-07-27 Wisconsin Alumni Research Foundation Method for localization and treatment of tumors using polylysine complexes
CN1056315C (zh) * 1993-05-31 2000-09-13 林海祥 聚肌胞复合物免疫佐剂及含有该佐剂的疫苗
DE69630514D1 (de) * 1995-01-05 2003-12-04 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
CA2203843C (en) * 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
CN1867355A (zh) 2003-08-11 2006-11-22 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
WO2005105838A2 (en) * 2004-04-28 2005-11-10 Paradigm Therapeutics Limited Ion channel
KR101203401B1 (ko) * 2005-06-08 2012-11-22 이쉥 바이오파마(싱가포르)피티이 리미티드 폴리이노신산-폴리시티딜산-기초 보조제
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant

Also Published As

Publication number Publication date
CN101166559A (zh) 2008-04-23
US20110212123A1 (en) 2011-09-01
TW200800258A (en) 2008-01-01
AU2006335367A1 (en) 2007-07-19
IL192746A0 (en) 2009-02-11
US20090175902A1 (en) 2009-07-09
EP1971402A4 (en) 2010-07-14
NZ570379A (en) 2012-07-27
RU2008133217A (ru) 2010-02-20
CN101166559B (zh) 2012-08-22
WO2007081287A9 (en) 2007-12-21
US8303966B2 (en) 2012-11-06
US20130115244A1 (en) 2013-05-09
MY150706A (en) 2014-02-28
EP1971402A1 (en) 2008-09-24
JP2009523721A (ja) 2009-06-25
US20070166800A1 (en) 2007-07-19
KR20080091106A (ko) 2008-10-09
BRPI0621181A2 (pt) 2011-11-22
WO2007081287A1 (en) 2007-07-19
BRPI0621181A8 (pt) 2017-09-12
ZA200806339B (en) 2010-03-31
TWI503125B (zh) 2015-10-11
CA2632415A1 (en) 2007-07-19
AU2006335367B2 (en) 2012-08-30
RU2462264C2 (ru) 2012-09-27
HK1112863A1 (en) 2008-09-19

Similar Documents

Publication Publication Date Title
CU23810A3 (es) Sustancias inmunogénicas que comprenden un adyuvante a base de ácido poliinosínico-ácido policitidílico
CU23819A3 (es) Sustancias inmunogénicas mucosales que comprenden un adyuvante a base de ácido poliinosínico-ácido policitidílico
UA94900C2 (uk) Вакцина
IL187616A (en) Use of an adjuvant compound containing polyinosinic acid – polycytidylic acid, antibiotics, and positive ion as an immunosuppressant
WO2010005735A3 (en) Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
MX2011003843A (es) Incorporacion de adyuvante en inmunonanoterapeuticos.
MX2010008799A (es) Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
CL2011000914A1 (es) Vacuna combinada estable completamente liquida que comprende antigenos difterico, tetanico, pertusico acelular, de haemophilus influenzae, y de virus de poliomielitis en donde el antigeno se haemophilus influenzae no esta sustancialmente absorbido sobre ningun adyuvante; y proceso de fabricacion.
CY1122911T1 (el) ΑΝΟΣΟΘΕΡΑΠΕΙΑ ΜΕ ΤΗ ΧΡΗΣΗ ΚΥΤΤΑΡΟΥ ΤΟ ΟΠΟΙΟ ΕΧΕΙ ΤΗΝ ΙΚΑΝΟΤΗΤΑ ΣΥΝΕΚΦΡΑΣΗΣ ΑΝΤΙΓΟΝΟΥ ΣΤΟΧΟΥ ΚΑΙ CD1d ΚΑΙ ΕΙΝΑΙ ΔΙΕΓΕΡΜΕΝΟ ΜΕ ΣΥΝΔΕΤΗ CD1d
UY30302A1 (es) Formulaciones de pepticuerpos terapeuticos liofilizados
CR10101A (es) Nueva composición
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
GB201009273D0 (en) Novel vaccine
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
BRPI0715396B8 (pt) método de produção de uma composição para vacina
CO6331297A2 (es) Composiciones adyuvantes novedosas
DK2101569T3 (da) Krystallinsk fast rasagilinbase
ECSP099410A (es) Adsorbente de fosfato a base de hierro (iii)-carbohidrato
NI201100025A (es) Métodos de administración de las formulaciones tópicas antimicóticas para el tratamiento de las infecciones por hongos.
CL2011003033A1 (es) Uso de un lipopolisacarido de ochrobactrum intermedium lmg3306 o de una composición que lo comprende para el tratamiento y/o prevencion de sepsis o enfermedades infecciosas; procedimiento para la preparacion del lipopolisacárido; y composicion que comprende el lipopolisacarido.
BRPI0821240B8 (pt) formas mutantes de estreptolisina o
EA200800837A1 (ru) Иммуностимулирующая одноцепочечная рибонуклеиновая кислота с фосфодиэфирным остовом
ES2549152T1 (es) Carragenano modificado mediante un procedimiento de intercambio iónico
BRPI0820258B8 (pt) composto, composições de vacina, e, uso de um composto
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа

Legal Events

Date Code Title Description
FG Grant of patent